Company Overview

Ajuo esn Psi-GAD Phase 2a trial design World-first clinical trial prioritising scientific independence and rigour for the best patient outcomes Incannex The Study A phase 2 randomised triple-blind active-placebo- controlled clinical trial Primary Outcomes Reduction in anxiety as measured using the Hamilton Anxiety Rating Scale Safety and Efficacy The safety, efficacy and tolerability of psilocybin- assisted psychotherapy Secondary Outcomes Quality of life, functional impairment and comorbidities Participants 72 participants that will experience two psilocybin or active- placebo dosing sessions Analysis A preliminary analysis of patient data will be conducted after 30 patients, full analysis at 72 patients Lead Assets ●●●●●●●●●● Psychotherapy Up to 11 non-drug, specialist psychotherapy sessions over a period of 10 weeks 2B Planning Preliminary analysis will inform the second part of the trial (n=42) and/or facilitate commencement of the phase 2b pivotal clinical trial Investor Presentation 33

View entire presentation